Assessed for eligibility

Slides:

Advertisements

Similar presentations

Intermediate stage HCC management

Advertisements

Bruix J, et al. Presented at the 44 th Annual Meeting of the European Association for the Study of the Liver (EASL), April 24, 2009, Copenhagen, Denmark.04/28/09.

Staging Strategy and Treatment for Patients With HCC

Cardiovascular outcome in patients with dysglycemia with daily supplementation of n-3 fatty acids 1 ORIGIN trial (Outcome Reduction with an Initial Glargine.

57445 HCC were registered HCC with complete data underwent surgical resection 9577 underwent local ablation therapies 9283 underwent TACE 1150.

ACRIN 6673 Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma in Cirrhotic Patients: A Multi-Center Study.

Portal Hypertension portal venous pressure > 5 mmHg

+ Liver Transplantation for PSC Patients A Transplant Surgeon’s Perspective Tiffany Anthony, MD Annette C. and Harold C. Simmons Transplant Institute Baylor.

FDA Presentation ODAC Meeting July NDA Applicant: Eli Lilly Evista ® (Raloxifene Hydrochloride)

Transjugular Intrahepatic Portosytemic Shunt Kevin A. Smith, MD Interventional Radiologist Roper Radiologists, PA.

Suppl Fig. 1a The clinical protocol is shown schematically.

Module 4: Central Randomization System (CRS). This training session contains information regarding: Overview of Data Collection & Entry Overview of Data.

Baseline Characteristics of the Patients* - Part I The ONTARGET Investigators. N Engl J Med 2008 [Epub on Mar 31]

Management of patients with cirrhosis and refractory ascites Treviso 4 Giugno 2009 P. Angeli Dept. of Clinical and Experimental Medicine University of.

Journal Club Leona Isabella von Köckritz.

Safety and efficacy of TACE and gamma knife on hepatocellular carcinoma with portal vein invasion Xiao-Jie Lu, Jing Dong, Li-Juan Ji, Jin-Hong Luo, Huang-Ming.

Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal- cell carcinoma after radical nephrectomy: phase III,

Dr. Mohammed Omar Khalifa

Safety and efficacy of irreversible electroporation (IRE) for the treatment of liver tumors Petter Frühling Kirurgkliniken Hudiksvall, Anders Nilsson Röntgen.

Hepatocellular Carcinoma: Diagnosis and Management

The efficacy and safety of oral Rivaroxaban in patients with permanent inferior vena cava filter: a pilot case-control study Lobastov K., Barinov V.,

World Tuberculosis Day 2014

464 assessed for eligibility

Fig. 4. First-line treatment according to 2014 KLCSG-NCC Korea Practice Guidelines for patients with HCC, Child-Pugh class A, no portal hypertension, and.

A randomized controlled trial of distal renal denervation vs conventional mode of the intervention for treatment of resistant hypertension Stanislav Pekarskiy.

Chapter 2: Identification and Care of Patients With CKD

Novel Pretreatment Scoring Incorporating C-reactive Protein to Predict Overall Survival in Advanced Hepatocellular Carcinoma with Sorafenib Treatment Liver.

SIRveNIB: Randomized Phase III Trial of Selective Internal Radiation Therapy vs Sorafenib in Locally Advanced HCC CCO Independent Conference Highlights*

Women’s Health Behaviours Following Referral to 3 Different

MATERIALS & METHODS BACKGROUND RESULTS OBJECTIVES SUMMARY

Radiofrequency ablation combined with hypertonic saline injection allows creation of coagulation zones similar to those created by microwave ablation Quesada,

Fig. 5. Receiver operating characteristic curve analyses showing diagnostic accuracy of ADC value for differentiating between bland and malignant PVT.Area.

Assessed for eligibility (n = 38)

Managing Complications of Cirrhosis

Assessed for eligibility (N = )

Volume 124, Issue 7, Pages (June 2003)

Shiv K. Sarin, Cyriac A. Philips Gastroenterology

Deep Vein Thrombosis and Pulmonary Embolism in a Mountain Guide: Awareness, Diagnostic Challenges, and Management Considerations at Altitude Claire M.

HEPATOCELLULAR CARCINOMA (HCC) at

World Tuberculosis Day 2016

World Tuberculosis Day 2014

Risk of de novo Hepatocellular Carcinoma after HCV Treatment with Direct-Acting Antivirals Liver Cancer - DOI: / Fig. 1. Flowchart of included.

Marcus-Alexander Wörns, Peter Robert Galle Journal of Hepatology

Volume 136, Issue 1, Pages (January 2009)

Volume 68, Issue 4, Pages (April 2018)

Accepted for analysis (n=232),

Chapter 2: Identification and Care of Patients with CKD

A randomized, placebo-controlled trial of doxycycline after endoluminal aneurysm repair Amy E. Hackmann, MD, Brian G. Rubin, MD, Luis A. Sanchez, MD,

Covering the Cover Gastroenterology

Number sequences - PowerPoint months

Liver cancer: Approaching a personalized care

A meta-analysis of anticoagulation for calf deep venous thrombosis

Long-term safety and efficacy of zotarolimus-eluting and sirolimus-eluting stents in routine clinical care patients 36-month follow-up in the SORT OUT.

G. Ippolito, A. Zumla, S. Lanini Clinical Microbiology and Infection

Lei Yu, Dana A. Sloane, Chuanfa Guo, Charles D. Howell

Clinical states of cirrhosis and competing risks

Theresa Hydes, William Gilmore, Nick Sheron, Ian Gilmore

Clinical Gastroenterology and Hepatology

TRANSPORT2 - Eligibility -

Liver Transplantation for Hepatocellular Carcinoma

Genetic alterations in advanced HBV-related HCC with portal vein tumor thrombosis: Insights from next generation DNA sequencing Roongruedee Chaiteerakij,

Results of a randomized clinical trial of external beam radiation to prevent restenosis after superficial femoral artery stenting Eric Therasse, MD,

Interferon free treatment

FIGURE 1. Flowchart of PnCRM7 clinical trial participants, primary efficacy cohort, and sub-populations used for efficacy analyses. Clinical trial participants.

Shiv K. Sarin, Cyriac A. Philips Gastroenterology

Utility of the MELD score for assessing 3-month survival in patients with liver cirrhosis: one more positive answer Edoardo Giannini, Federica Botta,

Figure 1. Flowchart for selection of study participants.

Multidisciplinary team approach to hepatocellular carcinoma management in a liver transplant center from Romania Cerban R.1, Iacob S.1, Croitoru A.1, Popescu.

Introduction to Abbreviated Liver MRI Protocols

Chapter 2: Identification and Care of Patients with CKD

Presentation transcript:

Assessed for eligibility (n=137) TIPS (n=29) LVP + A (n=33) Analysed (n=29) Lost to follow-up (n=1 ) Analysed (n=33) Excluded (n=75) Not meeting inclusion criteria (n=67)* Declined to participate (n=5) Other reasons (n=3) Randomized (n=62) age > 70 20 ChildC>12 17 > 6 LVP 13 Complete PVT 4 Cardiac failure associated indication (prevention of rebleeding) HCC 5 Age > 70 (n = 20), Child Pugh score >12 (n=17), more than 6 large volume paracentesis within the previous 3 months (n = 13), complete portal vein thrombosis( n=4), cardiac failure or pulmonary hypertension (n=4), associated indication (prevention of rebleeding : n = 4), hepatocellular carcinoma (n = 5)